Literature DB >> 3738291

Censoring distributions as a measure of follow-up in survival analysis.

E L Korn.   

Abstract

The mean or median of the follow-up times as a measure of the quality or completeness of the follow-up in a survival analysis can sometimes be misleading--a more severe disease will have shorter follow-up times because of earlier deaths. We suggest here that estimates of the censoring distribution provide a more useful measure of the follow-up. This paper gives estimation procedures for both grouped-time (cohort) data and continuous data, and provides an application.

Mesh：

Year:  1986        PMID： 3738291     DOI： 10.1002/sim.4780050306

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


  30 in total

1.  Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).

Authors:  Kristie A Blum; Mei-Yin Polley; Sin-Ho Jung; Travis J Dockter; Sarah Anderson; Eric D Hsi; Nina Wagner-Johnston; Beth Christian; Jim Atkins; Bruce D Cheson; John P Leonard; Nancy L Bartlett
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

2.  DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Authors:  V I Gaidzik; D Weber; P Paschka; A Kaumanns; S Krieger; A Corbacioglu; J Krönke; S Kapp-Schwoerer; D Krämer; H-A Horst; I Schmidt-Wolf; G Held; A Kündgen; M Ringhoffer; K Götze; T Kindler; W Fiedler; M Wattad; R F Schlenk; L Bullinger; V Teleanu; B Schlegelberger; F Thol; M Heuser; A Ganser; H Döhner; K Döhner
Journal:  Leukemia       Date:  2017-06-23       Impact factor: 11.528

3.  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Authors:  Felicitas Thol; Razif Gabdoulline; Alessandro Liebich; Piroska Klement; Johannes Schiller; Christian Kandziora; Lothar Hambach; Michael Stadler; Christian Koenecke; Madita Flintrop; Mira Pankratz; Martin Wichmann; Blerina Neziri; Konstantin Büttner; Bennet Heida; Sabrina Klesse; Anuhar Chaturvedi; Arnold Kloos; Gudrun Göhring; Brigitte Schlegelberger; Verena I Gaidzik; Lars Bullinger; Walter Fiedler; Albert Heim; Iyas Hamwi; Matthias Eder; Jürgen Krauter; Richard F Schlenk; Peter Paschka; Konstanze Döhner; Hartmut Döhner; Arnold Ganser; Michael Heuser
Journal:  Blood       Date:  2018-09-06       Impact factor: 22.113

4.  Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.

Authors:  F V Michelis; E G Atenafu; V Gupta; D D Kim; J Kuruvilla; J H Lipton; D Loach; M D Seftel; J Uhm; N Alam; A Lambie; L McGillis; H A Messner
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

5.  Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Authors:  F Thol; S Klesse; L Köhler; R Gabdoulline; A Kloos; A Liebich; M Wichmann; A Chaturvedi; J Fabisch; V I Gaidzik; P Paschka; L Bullinger; G Bug; H Serve; G Göhring; B Schlegelberger; M Lübbert; H Kirchner; M Wattad; D Kraemer; B Hertenstein; G Heil; W Fiedler; J Krauter; R F Schlenk; K Döhner; H Döhner; A Ganser; M Heuser
Journal:  Leukemia       Date:  2016-11-24       Impact factor: 11.528

6.  Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.

Authors:  Raphael Itzykson; Claude Gardin; Cécile Pautas; Xavier Thomas; Pascal Turlure; Emmanuel Raffoux; Christine Terré; Pierre Fenaux; Sylvie Castaigne; Hervé Dombret; Nicolas Boissel
Journal:  Haematologica       Date:  2011-04-01       Impact factor: 9.941

Review 7.  Measures of follow-up in time-to-event studies: Why provide them and what should they be?

Authors:  Rebecca A Betensky
Journal:  Clin Trials       Date:  2015-05-29       Impact factor: 2.486

8.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

9.  Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

Authors:  Matthew R Cooperberg; Elai Davicioni; Anamaria Crisan; Robert B Jenkins; Mercedeh Ghadessi; R Jeffrey Karnes
Journal:  Eur Urol       Date:  2014-07-02       Impact factor: 20.096

10.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Authors:  V I Gaidzik; V Teleanu; E Papaemmanuil; D Weber; P Paschka; J Hahn; T Wallrabenstein; B Kolbinger; C H Köhne; H A Horst; P Brossart; G Held; A Kündgen; M Ringhoffer; K Götze; M Rummel; M Gerstung; P Campbell; J M Kraus; H A Kestler; F Thol; M Heuser; B Schlegelberger; A Ganser; L Bullinger; R F Schlenk; K Döhner; H Döhner
Journal:  Leukemia       Date:  2016-05-03       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.